Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
STUDIO CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Every March, the International Myeloma Foundation (IMF) leads Myeloma Action Month — an annual global awareness campaign that raises awareness...
-
Leading Macau’s Non-Gaming Diversification Through Mice, Entertainment Events and Live Sports Q4 2025 Group Adjusted EBITDAUp 33% YoY and Up 29% QoQ to $4.3 Billion FY2025 Group Adjusted EBITDA Up...
-
NASHVILLE, Tenn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”) announced today that its subsidiaries, RHP Hotel Properties, LP (the “Operating...
-
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and...
-
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Questex’s Vibe Conference, the only event of its kind dedicated to the on-premise beverage industry, unveils the winners of the Jim Flaherty Industry...
-
NASHVILLE, Tenn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”) announced today that its subsidiaries, RHP Hotel Properties, LP (the “Operating...
-
BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today...
-
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
-
Crestline appoints iMaggie Moran SVP of Sales & Marketing.
-
Orlando, Florida, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The countdown is on as case managers and transitions of care professionals from across the country are preparing to gather in Orlando for the most...